home / stock / bivi / bivi news

BIVI News and Press, BioVie Inc. From 07/16/21

Stock Information
Company Name: BioVie Inc.
Stock Symbol: BIVI
Market: NASDAQ
Website: biovieinc.com
Menu
BIVI BIVI Quote BIVI Short BIVI News BIVI Articles BIVI Message Board
Get BIVI Alerts

News, Short Squeeze, Breakout and More Instantly...
BIVI - Basis for BioVie's Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer's Disease Published in Neurodegenerative Disease Management

SANTA MONICA, Calif., July 16, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease, neurodegenerative disease and certain cancers, announced today that an article summarizing the scientific rationale for the ...
BIVI - Development of BioVie's NE3107 Asset Featured by the American Diabetes Association

SANTA MONICA, Calif., June 29, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, announced today that a video documentary detailing the ...

BIVI - BioVie Added to Russell Microcap® Index

SANTA MONICA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced...

BIVI - BioVie Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

SANTA MONICA, Calif., June 24, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today announced ...
BIVI - BioVie gets FDA guidance for BIV201 development program

BioVie (BIVI) highlights feedback from the U.S. FDA related to the company's development program for BIV201 for the treatment of hepatorenal syndrome–acute kidney injury ((HRS-AKI)).Based on communications with the FDA, the company believes that positive results from a single pivo...

BIVI - BioVie Receives FDA Guidance for Phase 3 Clinical Trial of BIV201 in HRS-AKI

SANTA MONICA, Calif., June 23, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neurodegenerative disorders and certain cancers, today announced ...

BIVI - BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

SANTA MONICA, Calif., June 17, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"),a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers,, today announced...
BIVI - BioVie Announces Closing of Acquisition of BioPharma Assets from Privately Held NeurMedix

SANTA MONICA, Calif., June 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company") today announced the closing of its previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc., a privately held clinical-stage pharmaceutical company. The acqu...

BIVI - BioVie Hosting Research & Development Day

SANTA MONICA, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced ...

BIVI - BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix

SANTA MONICA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced amendments to certain terms for the previously announced acquisit...
Previous 10 Next 10